在医疗人员监督下，跨性别成年人的激素治疗是安全的；对跨性别者激素治疗后遗症的综述。
Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals.
作者信息
Weinand Jamie D, Safer Joshua D
机构信息
Transgender Medicine Research Group, Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Boston, MA, USA.
出版信息
J Clin Transl Endocrinol. 2015 Jun;2(2):55-60. doi: 10.1016/j.jcte.2015.02.003.
Abstract
INTRODUCTION
Some providers report concern for the safety of transgender hormone therapy (HT).
METHODS
This is a systematic literature review of HT safety for transgender adults.
RESULTS
Current literature suggests HT is safe when followed carefully for certain risks. The greatest health concern for HT in transgender women is venous thromboembolism. HT among transgender men appears to cause polycythemia. Both groups experienced elevated fasting glucose. There is no increase in cancer prevalence or mortality due to transgender HT.
CONCLUSION
Although current data support the safety of transgender HT with physician supervision, larger, long-term studies are needed in transgender medicine.
摘要
引言
一些医疗服务提供者报告了对跨性别激素治疗（HT）安全性的担忧。
方法
这是一项针对成年跨性别者HT安全性的系统文献综述。
结果
当前文献表明，在仔细关注某些风险的情况下，HT是安全的。跨性别女性接受HT时最大的健康问题是静脉血栓栓塞。跨性别男性接受HT似乎会导致红细胞增多症。两组的空腹血糖均有所升高。跨性别者接受HT不会导致癌症患病率或死亡率增加。
结论
尽管目前的数据支持在医生监督下跨性别者接受HT的安全性，但跨性别医学仍需要开展更大规模的长期研究。
相似文献
1
Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals.在医疗人员监督下，跨性别成年人的激素治疗是安全的；对跨性别者激素治疗后遗症的综述。
J Clin Transl Endocrinol. 2015 Jun;2(2):55-60. doi: 10.1016/j.jcte.2015.02.003.
2
Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review.评估和应对跨性别肯定护理谱中的静脉血栓栓塞风险：综述。
Endocr Pract. 2023 Apr;29(4):272-278. doi: 10.1016/j.eprac.2022.12.008. Epub 2022 Dec 17.
3
Corrigendum to "Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals" [J. JCTE 2 (2015) 55-60].《关于“在医疗人员监督下，跨性别成年人激素治疗是安全的；对跨性别者激素治疗后遗症的综述”的勘误》[J. JCTE 2 (2015) 55 - 60]
J Clin Transl Endocrinol. 2024 Mar 16;35:100334. doi: 10.1016/j.jcte.2024.100334. eCollection 2024 Mar.
4
Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy.管理接受激素治疗的成年跨性别者静脉血栓栓塞的风险。
J Blood Med. 2019 Jul 10;10:209-216. doi: 10.2147/JBM.S166780. eCollection 2019.
5
Risk for Venous Thromboembolism in Transgender Patients Undergoing Cross-Sex Hormone Treatment: A Systematic Review.跨性别患者在接受跨性别激素治疗时发生静脉血栓栓塞的风险：系统评价。
J Sex Med. 2021 Jul;18(7):1280-1291. doi: 10.1016/j.jsxm.2021.04.006. Epub 2021 Jun 16.
6
Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence.跨性别个体在开始接受激素治疗后性欲的变化：来自欧洲性别不一致调查纵向网络的结果。
J Sex Med. 2020 Apr;17(4):812-825. doi: 10.1016/j.jsxm.2019.12.020. Epub 2020 Jan 31.
8
Cardiovascular disease risk factors among transgender women in Chiang Mai, Thailand.泰国清迈跨性别女性的心血管疾病风险因素。
Am J Cardiovasc Dis. 2020 Jun 15;10(2):124-130. eCollection 2020.
9
CARDIOVASCULAR HEALTH MAINTENANCE IN AGING INDIVIDUALS: THE IMPLICATIONS FOR TRANSGENDER MEN AND WOMEN ON HORMONE THERAPY.心血管健康维护在老年个体中的应用：激素治疗对跨性别男性和女性的影响。
Endocr Pract. 2021 Jan;27(1):63-70. doi: 10.1016/j.eprac.2020.11.001. Epub 2020 Dec 13.
10
Primary care providers' willingness to continue gender-affirming hormone therapy for transgender patients.初级保健提供者继续为跨性别患者提供性别确认激素治疗的意愿。
Fam Pract. 2018 Sep 18;35(5):576-581. doi: 10.1093/fampra/cmx119.
引用本文的文献
1
Endocrine issues in critically ill transgender patients: A narrative review.危重症跨性别患者的内分泌问题：一项叙述性综述。
World J Crit Care Med. 2025 Sep 9;14(3):100660. doi: 10.5492/wjccm.v14.i3.100660.
2
Case Report: Ischemic stroke in a young transgender woman due to unsupervised estrogen therapy.病例报告：一名年轻的跨性别女性因未经监管的雌激素治疗引发缺血性中风。
Front Glob Womens Health. 2025 Aug 8;6:1588553. doi: 10.3389/fgwh.2025.1588553. eCollection 2025.
3
Prolactinoma Resection in a Transgender Woman on Gender-affirming Hormone Therapy.接受性别肯定激素治疗的跨性别女性的泌乳素瘤切除术
JCEM Case Rep. 2025 Jul 7;3(8):luaf120. doi: 10.1210/jcemcr/luaf120. eCollection 2025 Aug.
4
Body modification technologies and transvestite and trans people in Argentina: A quantitative study on inequalities in use and access.阿根廷的身体改造技术以及异装癖者和跨性别者：关于使用和获取方面不平等现象的定量研究。
Salud Colect. 2025 Mar 29;21:e5206. doi: 10.18294/sc.2025.5206.
5
Inflammation as a Potential Mechanism Contributing to Sexual Functioning Following Initiation of Gender-Affirming Hormone Therapy.炎症作为性别确认激素治疗开始后影响性功能的潜在机制。
Curr Sex Health Rep. 2024 Jun;16(2):104-118. doi: 10.1007/s11930-024-00385-2. Epub 2024 Apr 2.
6
"Ever since I knew I was trans I knew I wanted hormone therapy": a qualitative exploration into the journey of Australian trans individuals accessing feminizing gender-affirming hormone therapy.“从我知道自己是跨性别者起，我就知道自己想要激素治疗”：对澳大利亚跨性别者接受女性化性别确认激素治疗历程的质性探索。
Int J Transgend Health. 2023 Dec 11;25(4):840-854. doi: 10.1080/26895269.2023.2290132. eCollection 2024.
7
Biochemical liver damage during gender affirming therapy in trans adults assigned female at birth: a meta-analysis.出生时被指定为女性的成年跨性别者在性别肯定治疗期间的生化肝损伤：一项荟萃分析。
J Endocrinol Invest. 2025 Jan;48(1):161-171. doi: 10.1007/s40618-024-02418-y. Epub 2024 Jun 22.
8
Use of hormones and risk of venous thromboembolism.激素的使用与静脉血栓栓塞风险。
Rev Bras Ginecol Obstet. 2024 Apr 2;46. doi: 10.61622/rbgo/2024FPS02. eCollection 2024.
9
Effect of GnRH Active Immunisation on Reproductive Performance of Male Sprague Dawley Rats.促性腺激素释放激素主动免疫对雄性 Sprague Dawley 大鼠繁殖性能的影响。
Int J Mol Sci. 2024 Mar 11;25(6):3193. doi: 10.3390/ijms25063193.
10
Erythrocytosis in Gender-Affirming Care With Testosterone.性别肯定治疗中使用睾酮导致红细胞增多症。
Ann Fam Med. 2023 Sep-Oct;21(5):403-407. doi: 10.1370/afm.3018.
本文引用的文献
1
Diagnosis of prolactinoma in two male-to-female transsexual subjects following high-dose cross-sex hormone therapy.两名接受高剂量跨性别激素治疗的男变女变性者泌乳素瘤的诊断
Andrologia. 2015 Aug;47(6):680-4. doi: 10.1111/and.12317. Epub 2014 Jul 25.
2
Progress on the road to better medical care for transgender patients.为跨性别患者提供更好医疗护理的道路上取得的进展。
Curr Opin Endocrinol Diabetes Obes. 2013 Dec;20(6):553-8. doi: 10.1097/01.med.0000436188.95351.4d.
3
Interpreting laboratory results in transgender patients on hormone therapy.解读接受激素治疗的跨性别患者的实验室检查结果。
Am J Med. 2014 Feb;127(2):159-62. doi: 10.1016/j.amjmed.2013.10.009. Epub 2013 Oct 19.
4
Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens.接受雌激素治疗的去势男性变女性易性癖者的前列腺癌发病率。
Andrologia. 2014 Dec;46(10):1156-60. doi: 10.1111/and.12208. Epub 2013 Dec 12.
5
Sexual desire in trans persons: associations with sex reassignment treatment.跨性别者的性欲：与性别重置治疗的关联。
J Sex Med. 2014 Jan;11(1):107-18. doi: 10.1111/jsm.12365. Epub 2013 Oct 24.
6
Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.接受三十年雌激素治疗后被诊断出患有转移性前列腺癌的变性者
Can Urol Assoc J. 2013 Jul-Aug;7(7-8):E544-6. doi: 10.5489/cuaj.175.
7
Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.跨性别者接受跨性别激素治疗后的乳腺癌发展。
J Sex Med. 2013 Dec;10(12):3129-34. doi: 10.1111/jsm.12319. Epub 2013 Sep 9.
8
[Morphological and functional changes of organs of female and male reproductive systems at change of sex].
Urologiia. 2013 May-Jun(3):18-23.
9
Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review.静脉血栓栓塞作为男性向女性变性者跨性别激素治疗的并发症：一项综述。
Andrologia. 2014 Sep;46(7):791-5. doi: 10.1111/and.12150. Epub 2013 Aug 15.
10
Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study.跨性别者在接受跨性别激素治疗期间患心血管疾病和癌症的流行情况：一项大型队列病例对照研究。
Eur J Endocrinol. 2013 Sep 13;169(4):471-8. doi: 10.1530/EJE-13-0493. Print 2013 Oct.
Zotero 插件